Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- B of A -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2)	9/25/2002 8:21:18 AM
From: Icebrg	Read Replies (2) \| Respond to of 33

Banc of America Securities analyst Mike King upgraded OSI to buy from market perform Wednesday, based on the bullish impact of the Iressa decision. OSI's drug, Tarceva, is very similar to Iressa, so the company's shares had been under heavy selling pressure in sympathy with AstraZeneca. Now that cloud has cleared, says King. OSI looks even more attractive now, he adds, because the company is already conducting the kind of randomized, controlled study of Tarceva that the FDA and its advisory panel still wants AstraZeneca to do with Iressa. King's firm doesn't have a banking relationship with OSI, but he recently left now-defunct Robertson Stephens, which did underwriting work for OSI while he was an analyst there.